BEAM is trading at $35.80 (+4.31%) after hours, reversing part of its June 30 pullback despite no major company-specific announcements, earnings releases, or FDA events identified.
- The move is consistent with broader market strength and a risk-on environment, with the Nasdaq up 1.52% and the S&P 500 up 0.70%.
- Growth and biotech names saw continued momentum during the session, contributing to the upward price action.